Terminology Service for NFDI4Health
JSON

Palbociclib

Go to external page http://purl.obolibrary.org/obo/NCIT_C49176

An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. [ ]

Term info

Label

Palbociclib

Synonyms
  • 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
  • Ibrance
  • PALBOCICLIB
  • PD 0332991
  • PD 332991
  • PD 991
  • PD-0332991
  • Palbociclib
  • Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712

Accepted Therapeutic Use For

hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer

CAS Registry

571190-30-2

Chemical Formula

C24H29N7O2

Display Name

Palbociclib

FDA UNII Code

G9ZF61LE7G

Legacy Concept Name

PD-0332991

Preferred Name

Palbociclib

Semantic Type

Pharmacologic Substance, Organic Chemical

UMLS CUI

C3853822

code

C49176